Abstract:Major epigenetic changes are associated with carcinogenesis, including aberrant DNA methylations and post-translational modifications of histone. Indeed evidence accumulated in recent years indicates that inactivating DNA hypermethylation preferentially targets the subset of polycomb group (PcG) genes that are regulators of developmental processes. Conversely, activating DNA hypomethylation targets oncogenic signaling pathway genes, but outcomes of both events lead in the overexpression of oncogenic signaling pathways that contribute to the stem-like state of cancer cells. On the basis of recent evidence from population-basedclinical and experimental studies, we hypothesize that factors associated with risk for developing a hematologic malignancy (HM), such as metabolic syndrome and chronic inflammation, may trigger epigenetic mechanisms to increase the transcriptional expression of oncogenes and activate oncogenic signaling pathways. Signaling pathways associated with such risk factors include but are not limited to pro-inflammatory nuclear factor κB (NF-κB) and mitogenic, growth, and survival Janus kinase (JAK) intracellular non-receptor tyrosine kinase-triggered pathways. The latter includes signaling pathways such as transducer and activator of transcription (STAT), Ras GTPases/mitogen-activated protein kinases (MAPKs)/extracellular signal-related kinases (ERKs), phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and β-catenin pathways. Recent findings on epigenetic mechanisms at work in the biology of cancer and in HMs and their importance in the etiology and pathogenesis of these diseases are herein summarized and discussed. Furthermore, the role of epigenetic processes in the determination of biological identity, the consequences for interindividual variability in disease clinical profile, and the potential of epigenetic drugs in HMs are also considered.

Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies

The Progress of Epigenetic Modification in Hematological Malignancies Research

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Dna Methyltransferases in Hematologic Malignancies

Research Progress of Epigenetics in Malignant Hematological Diseases

Epigenetic modifications in hematopoietic ecosystem: a key tuner from homeostasis to acute myeloid leukemia

Epigenetic-modifying agents: The potential game changers in the treatment of hematologic malignancies

Targeted Treatment of Acute Myeloid Leukemia Based on Epigenetic Regulation Mechanism

Epigenetic Regulation in Cancer Therapy: from Mechanisms to Clinical Advances

The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies

Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies

Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options

Long noncoding RNAs and their epigenetic function in hematological diseases

Physio-pathological Effects of N6-methyladenosine and Its Therapeutic Implications in Leukemia

Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy

Methylation alterations and advance of treatment in lymphoma

Epigenetic regulation in myelodysplastic syndromes: implications for therapy

Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis

Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets

A new perspective on hematological malignancies: m6A modification in immune microenvironment

The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia